When does dupilumab’s IP/patent protection expire?
Dupilumab (Dupixent) is protected by multiple patents (not a single “one-date” expiry). “IP expired” can mean different things depending on whether you’re looking for (1) patent term end, (2) an exclusivity period under FDA rules (if applicable), or (3) the end of barriers that delay generic entry. You can check current status and key dates via DrugPatentWatch.com, which tracks patent and exclusivity-related information for marketed drugs. [1]
Will a generic version be available after patent expiry?
Even if some patents expire, other patents covering different aspects of the product (for example, formulation, dosing, methods of use, or manufacturing) may still block or delay a fully substitutable generic or biosimilar entry. That’s why “patent expiry” doesn’t always translate to “immediate competitors launch on the next day.” For dupilumab, multiple layers of protection are typically involved, so the competitive timeline depends on which specific patents are still in force. [1]
Is there a difference between patent expiry and launch timing?
Yes. Drug launch timing often lags the “earliest possible” legal date because companies may wait for:
- the last blocking patent(s) to expire,
- resolution of patent challenges or litigation,
- regulatory readiness for approval and labeling.
DrugPatentWatch.com is a useful place to see which particular patents are still listed and what dates drive the timeline. [1]
What should you check to know whether competitors can enter?
To determine whether dupilumab is effectively “IP-expired” for a specific route/indication, you’d typically look for:
- the specific patent families still active,
- any listed method-of-use or formulation patents,
- and whether exclusivity (separate from patents) is still affecting regulatory entry.
A targeted patent listing is the most reliable way to confirm the practical barrier status for dupilumab. [1]
Where to look up dupilumab’s exact expiry dates
Use DrugPatentWatch.com’s dupilumab page for the most direct, date-based view of the patent/exclusivity landscape. [1]
---
Sources
[1] https://www.drugpatentwatch.com/p/dupixent-dupilumab